On Tuesday, Shares of Fitbit Inc. (NYSE:FIT), gained 2.21% to $37.88.
Fitbit, declared the closing of its initial public offering of Class A common stock and the full exercise of the underwriters’ option to purchase 5,486,250 additional shares. Fitbit sold 22,387,500 shares and the selling stockholders sold 19,673,750 shares, counting the shares sold upon exercise of the underwriters’ option to purchase additional shares, for a total of $841.2 million in aggregate gross proceeds to Fitbit and the selling stockholders.
Morgan Stanley, Deutsche Bank Securities, and BofA Merrill Lynch acted as active joint book-running managers for the offering. Barclays and SunTrust Robinson Humphrey acted as passive joint book-running managers and Piper Jaffray, Raymond James, Stifel, and William Blair acted as co-managers.
Fitbit Inc. provides wearable fitness-tracking devices worldwide. The company makes both wrist bands and clippable devices that monitor a user’s fitness activity by tracking the calories burned or distance covered.
Shares of Denbury Resources Inc. (NYSE:DNR), inclined 4.31% to $6.54, during its last trading session, as oil prices gained Tuesday, fueled by expectations of a drop in U.S. crude-oil and gasoline supplies.
The U.S. crude-oil benchmark, known as West Texas Intermediate, settled up 63 cents, or 1%, at $61.01 a barrel on the New York Mercantile Exchange. Brent, the global benchmark, rose $1.11, or 1.8%, to $64.45 a barrel on ICE Futures Europe. WSJ Reports.
Denbury Resources Inc. operates as an independent oil and natural gas company in the United States. The company primarily focuses on improved oil recovery utilizing carbon dioxide. It holds properties located in Mississippi, Texas, Louisiana, and Alabama in the Gulf Coast region; and in Montana, North Dakota, and Wyoming in the Rocky Mountain region.
Finally, XOMA Corporation (NASDAQ:XOMA), ended its last trade with -0.23% loss, and closed at $4.27.
XOMA Corporation, declared XOMA 358, a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism (HI).
Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, in addition to tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance, and waiver of Prescription Drug User Fee Act (PDUFA) filing fees. The OOPD also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
